Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Albert Einstein College of Medicine
Hoosier Cancer Research Network
University Hospital Heidelberg
University Health Network, Toronto
Eastern Cooperative Oncology Group
Rutgers, The State University of New Jersey
Sumitomo Pharma America, Inc.
Cedars-Sinai Medical Center
Case Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
Ohio State University Comprehensive Cancer Center
MacroGenics
Columbia University
Emory University
Medical College of Wisconsin
University of Nebraska
National Cancer Institute (NCI)
University of Washington
Medical College of Wisconsin
Novartis
Brigham and Women's Hospital
National Institutes of Health Clinical Center (CC)